共 50 条
- [31] Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2015, 26 (09) : 1904 - 1910Dieras, V.Campone, M.Yardley, D. A.Romieu, G.Valero, V.Isakoff, S. J.Koeppen, H.Wilson, T. R.Xiao, Y.Shames, D. S.Mocci, S.Chen, M.Schmid, P.
- [32] Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)Schmid, PeterAbraham, JacintaChan, StephenWheatley, DuncanBrunt, Adrian MurrayNemsadze, GiaBaird, Richard D.Park, Yeon HeeHall, Peter S.Perren, TimothyStein, Robert C.Mangel, LaszloFerrero, Jean-MarcPhillips, MelissaConibear, JohnCortes, JavierFoxley, Andrewde Bruin, Elza C.McEwen, RobertStetson, DanielDougherty, BrianSarker, Shah-JalalPrendergast, AaronMcLaughlin-Callan, MaxBurgess, MatthewLawrence, CherylCartwright, HayleyMousa, KellyTurner, Nicholas C.
- [33] A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple -Negative Breast Cancer.CANCER RESEARCH, 2011, 71Daniel, B. R.Campone, M.Dieras, V.Ervin, T.Yu, W.Paton, V. E.Xia, Q.Peterson, A.
- [34] Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancerEUROPEAN JOURNAL OF CANCER, 2018, 90 : 153 - 155Miles, DavidCameron, DavidHilton, MagalieGarcia, JosepO'Shaughnessy, Joyce
- [35] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)CANCER RESEARCH, 2016, 76Emens, L.Adams, S.Loi, S.Schmid, P.Schneeweiss, A.Rugo, H.Chui, S.Winer, E.
- [36] A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast CancerCANCER RESEARCH, 2009, 69 (24) : 496S - 496SGradishar, W. J.Kaklamani, VSahoo, Prasad T.Lokanatha, D.Raina, VBondarde, S.Jain, M.
- [37] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552Di Leo, AngeloGomez, Henry L.Aziz, ZebaZvirbule, ZaneteBines, JoseArbushites, Michael C.Guerrera, Stephanie F.Koehler, MariaOliva, CristinaStein, Steven H.Williams, Lisa S.Dering, JudyFinn, Richard S.Press, Michael F.
- [38] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerNATURE COMMUNICATIONS, 2022, 13 (01)Wang, BiyunSun, TaoZhao, YannanWang, ShusenZhang, JianWang, ZhonghuaTeng, Yue-ECai, LiYan, MinWang, XiaojiaJiang, ZefeiPan, YueyinLuo, JianfengShao, ZhiminWu, JiongGuo, XiaomaoHu, Xichun
- [39] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerNature Communications, 13Biyun WangTao SunYannan ZhaoShusen WangJian ZhangZhonghua WangYue-E TengLi CaiMin YanXiaojia WangZefei JiangYueyin PanJianfeng LuoZhimin ShaoJiong WuXiaomao GuoXichun Hu
- [40] Efficacy and safety of first-line atezolizumab plus bevacizumab plus paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trialCANCER RESEARCH, 2024, 84 (09)Gion, MariaCortez-Castedo, PatriciaBlancas, IsabelCortes, AlfonsoMarme, FrederikBlanch, SalvadorMurillo, Serafin MoralesDiaz, NievesCalvo-Plaza, IsabelRecalde, SabelaMartinez-Bueno, AlejandroRuiz-Borrego, ManuelLlabres, ElisendaTaberner, Maria Teresade Laurentiis, MichelinoGarcia-Saenz, Jose AngelRepkova, JanaAnton, AntonioGligorov, Josephde la Cruz, SusanaHoffmann, OliverMedioni, JacquesPhillips, MelissaSampayo-Cordero, MiguelAlcala-Lopez, DanielPerez-Garcia, Jose ManuelLlombart-Cussac, AntonioCortes, Javier